CMT Research Foundation
  • 2022 Global CMT Research Convention
  • What is CMT?
    • Types of CMT
      • What is CMT1?
      • What is CMT2?
      • What is CMT4?
      • What is CMTX?
        • Understanding CMT1X/CMTX1 and GJB1
    • Videos
      • What is CMT?
      • Everything You Need to Know in Five Minutes
      • Demystifying the Drug Development Process
      • How Patients Can Change the Pace of Drug Development
      • How We Get from Today to FDA-Approved Treatments
      • Conversations with Researchers Working in CMT
  • Our Team
    • Founders
    • Board of Directors
    • Scientific Advisory Board
    • Young Professionals Board
    • Ambassadors
    • CMT Research Foundation Staff
    • CMT Research Foundation Advisors
    • Contact Us
  • Research
    • Overview
    • Research Pipeline
    • Research News
    • Research We Fund
    • Clinical Trials
    • CMTRF Research Priorities
    • Apply for CMT Research Foundation Funding
  • News & Events
    • News & Opinion
    • 2022 Global CMT Research Convention
    • 2021 Global CMT Research Convention
  • Financials
  • Donate
Select Page

Give now to accelerate treatments and cures for all types of CMT.

Donate today!

Shift Pharmaceuticals Completes CMT Research Foundation-Funded Project, Will Continue Development of Gene Therapy for CMT1A

May 4, 2022 | CMT Research Updates, CMTRF Funded Research, News, Press Releases, Research news

By Keith Fargo, Chief Scientific Officer The CMT Research Foundation is pleased to announce that Shift Pharmaceuticals (Shift) has successfully completed their CMT Research Foundation-funded RNA-based therapy project. Shift created and tested a library of novel...

The Power of Scientific Collaboration – New Biomarkers for CMT

Mar 22, 2022 | About CMT, News, Research news

By Keith Fargo, Chief Scientific Officer At the CMT Research Foundation, we believe that more is achieved when people work together than when they work individually. This is especially true in biomedical research. Over the past few decades, a seismic shift has...

Gene therapy project for CMT2E has completed Milestone 1 successfully.

Feb 23, 2022 | CMT Research Updates, CMTRF Funded Research, Research news

University of Missouri features CMT in a video about the project and the role of precision medicine to treat CMT. By: Susan Ruediger, Co Founder and Chief Mission Officer With the recent opening of their new NextGen Precision Health Institute, University of Missouri...

AcuraStem Completes CMT Research Foundation-Funded Project, Finds Eleven Potential Therapeutics for CMT2A

Feb 11, 2022 | CMT Research Updates, CMTRF Funded Research, Research news

By Keith Fargo, Chief Scientific Officer The CMT Research Foundation is pleased to announce that the research team at AcuraStem has completed their CMT Research Foundation-funded drug screening project and has found eleven potential therapeutics for CMT2A....

CMT Research Foundation funds cutting edge research to deliver therapeutics to the peripheral nervous system

Nov 19, 2021 | CMT Research Updates, CMTRF Funded Research, Drug Development, Research news

The CMT Research Foundation has awarded nearly $100,000 to support a 13-month project to test a new therapeutic delivery system that may be capable of crossing the blood-nerve barrier and releasing therapeutic payloads to the Schwann cells and axons of the peripheral...

Boost for CMT Research with a $3 Million MRFF Grant Awarded for Improving the Diagnosis of Rare Neurogenetic Diseases

Jul 18, 2021 | CMT Research Updates, News, Research news

Professor Marina Kennerson who directs the team at the Northcott Neuroscience Laboratory, ANZAC Research Institute in Sydney Australia is one of the lead researchers awarded a $3 million grant from the Medical Research Future Fund (MRFF) Genomics Health Futures...
« Older Entries

Search Articles

Categories

  • About CMT
  • CMT Research Updates
  • CMTRF Funded Research
  • Drug Development
  • Gene Therapy
  • Life with CMT
  • News
  • Press Releases
  • Research news
  • Small Molecule Therapies
  • Stories
  • Therapy Types
  • Uncategorized

RSS Important Research News Announcements

  • A translatable RNAi-driven gene therapy silences PMP22/Pmp22 genes and improves neuropathy in CMT1A mice May 17, 2022
  • Original Surgical Treatment and Long-term Follow-up for Chronic Inflammatory Demyelinating Polyradiculoneuropathy Causing A Compressive Cervical Myelopathy May 17, 2022
  • Structural insights into Charcot-Marie-Tooth disease-linked mutations in human GDAP1 May 5, 2022
  • Treatment with IFB-088 Improves Neuropathy in CMT1A and CMT1B Mice May 2, 2022
  • Determine the Safety and Dose of EN001 in Patients With Charcot-Marie-Tooth Disease Type 1A April 19, 2022
  • Generation of a human induced pluripotent stem cell (iPSC) line (JUCTCi019-A) from a patient with Charcot-Marie-Tooth disease type 2A2 (CMT2A2) due to a heterozygous missense substitution c.2119C > T (p.Arg707Trp) in MFN2 gene April 12, 2022
  • Dosage effects of PMP22 on nonmyelinating Schwann cells in hereditary neuropathy with liability to pressure palsies April 9, 2022
  • The Antiepileptic Valproic Acid Ameliorates Charcot-Marie-Tooth 2W (CMT2W) Disease-Associated HARS1 Mutation-Induced Inhibition of Neuronal Cell Morphological Differentiation Through c-Jun N-terminal Kinase April 5, 2022
  • Therapeutic Potential of CKD-504, a Novel Selective Histone Deacetylase 6 Inhibitor March 30, 2022
  • Curcumin and Ethanol Effects in Trembler-J Schwann Cell Culture March 29, 2022

This website uses cookies to improve your experience. Full details can be found here. Cookie settingsACCEPT REJECT
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Non-necessary
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
SAVE & ACCEPT